Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?

It has been about a month since the last earnings report for Bio-Rad Laboratories (BIO). Shares have added about 11.7% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Bio-Rad due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Bio-Rad Laboratories, Inc. before we dive into how investors and analysts have reacted as of late.

Bio-Rad Q2 Earnings Beat, Revenues Miss Estimates

Bio-Rad Laboratories posted second-quarter 2026 adjusted earnings per share of $2.62, which surpassed the Zacks Consensus Estimate by 12%. The bottom line increased 0.4% from the prior-year quarter’s level.

The company’s second-quarter GAAP earnings were $13.85 per share compared with $11.67 a year ago.

BIO's Revenues

Second-quarter revenues of $651 million missed the Zacks Consensus Estimate by 1%. The figure remained flat year over year (down 1.9% at constant exchange rate or CER).

Bio-Rad’s 2026 Guidance

Bio-Rad expects non-GAAP, currency-neutral revenues to be in the range of a decline of approximately 3% to growth of approximately 0.5%. 

The company also expects a  non-GAAP operating margin of approximately 10% to 12%. 

How Have Estimates Been Moving Since Then?

Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.

VGM Scores

Currently, Bio-Rad has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Following the exact same course, the stock was allocated a score of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Bio-Rad has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

Bio-Rad belongs to the Zacks Medical - Products industry. Another stock from the same industry, Neogen (NEOG), has gained 3.6% over the past month. More than a month has passed since the company reported results for the quarter ended May 2026.

Neogen reported revenues of $225.3 million in the last reported quarter, representing a year-over-year change of -0.1%. EPS of $0.09 for the same period compares with $0.05 a year ago.

Neogen is expected to post earnings of $0.05 per share for the current quarter, representing a year-over-year change of +25%. Over the last 30 days, the Zacks Consensus Estimate has changed +4.4%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #2 (Buy) for Neogen. Also, the stock has a VGM Score of B.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research